tbuckley/cabot-search huggingface dataset:
IMST-30. EVALUATING THE IN-VITRO EFFECTS OF TUMOR-TREATING FIELDS ON T-CELL RESPONSES
Authors: Gil Diamant, Zvi Ram, Ilan Volovitz
Journal: Neuro-Oncology (2016)

Tumor Treating Fields (TTFields) are low-intensity electrical fields that target proliferating cells by hindering the formation of mitotic spindle and the translocation of charged organelles. Combining TTFields with immune-based therapies is a rational approach as they possess different mechanisms of action (MOA). Conversely, TTFields may potentially abrogate various cellular functions required for effective T cell responses. In this study we evaluated the effect of TTFields on select human T cell functions which are pivotal for an effective anti-tumoral response. Peripheral blood mononuclear cells (PBMC) were isolated from healthy donors. Cells were cultured with or without Phytohemaglutenin (PHA, an activating mitogenic superantigen) and under normal versus TTFields conditions. Cellular responses were monitored using an 8-color flow cytometry panel concurrently evaluating proliferation (CFSE), cytokine secretion (IFNɣ), cytotoxic degranulation (CD107a), and T cell activation/exhaustion (PD1 expression). TTFields did not alter the functionality of non-activated T cells. Viable, PHA-activated T cells treated with TTFields exhibited no change in their PD1 up-regulation (activation), in their IFNγ secretion and in their CD107a surface-expression (cytotoxicity). Viable, PHA-activated T cells exhibited reduced proliferation, in line with TTFields known MOA. Polyfunctionality, e.g., the secretion of more than one cytokine by a single T cell, is associated with effective anti-pathogen and anti-tumoral responses. A polyfunctionality analysis of the activated T cells demonstrated that under TTFields conditions, T cells that had lost the capacity to proliferate retained all other polyfunctional /combinatorical immune functions. All findings were true both for T helpers and for cytotoxic T cells. Pivotal T cell response parameters, with the exception of proliferation, were found to be unhindered by TTFields. The data suggests that the integration of TTFields with various immunotherapeutic approaches may be a rational approach to explore for the treatment of brain tumors.
Glycoproteins: Structure, Metabolism and Biology
Authors: Robert G. Spiro
Journal: New England Journal of Medicine (1963)

Biologic PropertiesSeveral of the plasma glycoproteins demonstrate specific binding properties, being responsible for the transport of such materials as copper (ceruloplasmin), iron (transferrin), hemoglobin (haptoglobin) and thyroxine (thyroxine-binding protein).Other functions of plasma glycoproteins include the participation of prothrombin and fibrinogen in the clotting process and the role of both the 7S and 19S gamma globulins as antibodies. The biologic function of the glycoprotein hormones and thyroglobulin are well known.The glycoproteins of various mucous secretions have a major role in raising the viscosity of these fluids, which in turn have a lubricating and protective role.Some glycoproteins have . . .
Hope
Authors: Kevin Hadduck
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reply to Glen Denmer Santok and Koon Ho Rha’s Letter to the Editor re: Pär Stattin, Fredrik Sandin, Frederik Birkebæk Thomsen, et al. Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.07.023
Authors: Pär Stattin, Ola Bratt
Journal: European Urology (2016)
Macular Degeneration
Authors: Edwin M. Stone
Journal: Annual Review of Medicine (2006)

Macular degeneration is a term that describes a large group of conditions that are collectively the most common cause of irreversible vision loss in the developed world. Approximately one in three people will be affected to some degree by the time they reach 75 years of age. Many forms of macular degeneration have a significant genetic component, and a large amount of progress has recently been made in understanding the genes involved. In the future, genetic testing may allow specific preventive treatments to be delivered to individuals at risk, decades before the disease would ordinarily become manifest.
Global trends in adolescent health
Authors: R. W. Blum
Journal: JAMA (1991)

Increasingly, morbidity and mortality trends for young people in developing nations are paralleling those in the industrialized world. As infectious causes of mortality diminish, unintentional injuries, suicide, homicide, war, and maternal mortality represent the primary causes of death in the second decade of life for most nations where data are maintained. As developing nations increasingly place priority on the education of their youth, early marriage and precocious child rearing are discouraged, and other problems, such as out-of-wedlock childbirth and illicit abortions, emerge. Problems such as substance abuse and suicide arise with the urban migration, increased unemployment, and disruption of traditional social structures that are experienced as developing countries industrialize. (<i>JAMA</i>. 1991;265:2711-2719)
Lyme Disease Surveillance —United States, 1989-1990
Journal: JAMA (1991)

Surveillance for Lyme disease (LD) was initiated by CDC in 1982 (1), and in January 1991, LD became nationally reportable (2). Forty-six states reported cases in 1989 and 1990 (Figure 1), but the occurrence in nature of the causative bacterium, Borrelia burgdorferi, has not been documented in all of these states. From 1982 through 1989, the annual reported number of cases of LD increased 18-fold (from 497 to 8803, respectively) and from 1986 through 1989, nearly doubled each year (Figure 2). The provisional total of 7997 cases for 1990 suggests a plateau in this trend of rapid annual increase. This report summarizes surveillance of LD during 1990 in Connecticut, Georgia, Michigan, Missouri, New Jersey, and Wisconsin.
Margaret McCartney: Getting the abstract in perspective
Journal: BMJ (2018)

k2499), the terms "sensitivity" and "specificity" were used in place of one another in one sentence.Where the column read "A blood test, performed prospectively in people with and people in a control group, can find a DNA marker with a high degree of sensitivity in patients with cancer but has varying, and not very high, specificity (from 56% upwards).,"it should have read "A blood test, performed prospectively in people with cancer and people in a control group, can find a DNA marker in patients with cancer at 95% specificity, but an accompanying, and not very high, sensitivity (varying from 56% upwards).
Halothane Arrhythmia
Authors: Walter Silver
Journal: JAMA (1976)

<h3>To the Editor.—</h3> We would like to comment on the statement by Drs Marks and Wallace that "clinically significant arrhythmias rarely occur when halothane is used in healthy young adults (or children), and when they do occur, they are usually associated with additional intraoperative events such as endotracheal intubation or surgical stimulation" (236:139, 1976). For the past few months, we have studied standard lead II rhythm strips of infants and children admitted to the hospital for surgery. Our protocol calls for such rhythm strips to be taken before and after premedication, during induction of anesthesia, during various stages of anesthesia, and in the recovery area. The right panels of the Figure are examples of some of the arrhythmias that have developed with the use of halothane. The panels on the left represent the normal rhythm of these children before induction with halothane. Rhythm strip E' shows a bizarre chaotic pattern;
MECHANICAL THERAPEUTIC AGENCIES.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Table of Contents
Authors: William Shearer, Donald Leung, David Chaplin, Stuart Turvey, David Broide, Francisco Bonilla, Hans Oettgen, Harry Schroeder, Lisa Cavacini, Scott Commins, Larry Borish, John Steinke, Kelly Stone, Calman Prussin, Dean Metcalfe, John Holloway, Ian Yang, Stephen Holgate, Robert Lemanske, William Busse, Mark Dykewicz, Daniel Hamilos, Scott Sicherer, Hugh Sampson, New York, David Khan, Roland Solensky, Luz Fonacier, Stephen Dreskin, Aurora Denver, David Peden, Charles Reed, Chapel Hill, Anaphylaxis S161, F Estelle, R Simons, Luigi Notarangelo, Javier Chinen, Amy Joseph, Richard Brasington, Leslie Kahl, Prabha Ranganathan, Tammy Cheng, John Atkinson, St Louis, Carol Langford, Aaron Michels, George Eisenbarth, Glenn Furuta, Michael Frank, Theresa Whiteside, Robert Hamilton
Journal: Journal of Allergy and Clinical Immunology (2010)
Correction: The Reliability of Medical Record Review for Estimating Adverse Event Rates
Journal: Annals of Internal Medicine (2002)

Corrections16 July 2002Correction: The Reliability of Medical Record Review for Estimating Adverse Event RatesFREESearch for more papers by this authorhttps://doi.org/10.7326/0003-4819-137-2-200207160-00026 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In a recent Brief Communication (1), the name of the second author, Stuart R. Lipsitz, PhD, was omitted from the byline. The byline should read “Eric J. Thomas, MD, MPH; Stuart R. Lipsitz, PhD; David M. Studdert, LLB, ScD, MPH; and Troyen A. Brennan, MD, JD, MPH.”Reference1. Thomas EJ, Lipsitz SR, Studdert DM, Brennan TA. The reliability of medical record review for estimating adverse event rates. Ann Intern Med. 2002;136:812-6. [PMID: 12044129] LinkGoogle Scholar Comments 0 Comments Sign In to Submit A Comment PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoThe Reliability of Medical Record Review for Estimating Adverse Event Rates Eric J. Thomas , Stuart R. Lipsitz , David M. Studdert , and Troyen A. Brennan Metrics 16 July 2002Volume 137, Issue 2 Page: 147 Keywords Adverse events ePublished: 16 July 2002 Issue Published: 16 July 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Prolactin modulates the naive B cell repertoire
Authors: Elena Peeva, Daniel Michael, James Cleary, Jeffrey Rice, Xian Chen, Betty Diamond
Journal: Journal of Clinical Investigation (2003)

Prolactin is a peptide hormone produced by the anterior pituitary gland that is critical in lactation. Prolactin can also be produced by lymphocytes, and both B and T cells express prolactin receptors. These findings have suggested that prolactin has immunomodulatory functions. Studies in spontaneously autoimmune hosts have demonstrated a role for prolactin in augmenting autoreactivity. We chose to analyze prolactin effects on anti-DNA B cells in nonspontaneously autoimmune female BALB/c mice transgenic for the heavy chain of an anti-DNA antibody. Treatment with prolactin for 4 weeks induced a lupus-like phenotype with an increased number of transgene-expressing B cells, elevated serum anti-DNA antibody titers, and glomerular immunoglobulin deposits. Prolactin caused a decrease in the population of transitional B cells and an increase in mature follicular and marginal zone B cells. The DNA-reactive B cells had a follicular cell phenotype. Anti-DNA hybridomas demonstrated that prolactin alters selection of the naive B cell repertoire. The expansion and activation of anti-DNA B cells in prolactin-treated R4A-γ2b BALB/c mice was dependent on the presence of CD4+ T cells. Finally, treatment with prolactin was unable to break tolerance in R4A-γ2b transgenic C57Bl/6 mice, suggesting that responsiveness of the immune system to prolactin is genetically determined.
Abstract 5145: A new discovering motif on SOS1 PR domain clues Grb2-SOS1 association
Authors: Tsung-Jen Liao, Hyunbum Jang, Ruth Nussinov, David Fushman
Journal: Cancer Research (2019)

Abstract Grb2 is an adaptor protein that recruits Ras-specific guanine nucleotide exchange factor (GEF), such as Son of sevenless 1 (SOS1), to the plasma membrane. SOS1 exchanges GDP by GTP, activating Ras. Grb2 consists of an SH2 domain in the middle and flanks nSH3/cSH3 domains at both ends. Both nSH3/cSH3 domains bind to SOS1’s C-terminal proline rich (PR) domain and have the preference for interacting with the PXXPXR motif. Our NMR data suggest that the arginine residue, followed by prolines in the PXXPXR motif, is responsible for the SH3-SOS1 association, yielding large chemical shift perturbations (CSPs) on the binding interface of SH3. The SOS1’s PR motif, PVPPPVPPRRRP, exhibits the strongest binding affinity to both SH3 domains. Using comprehensive techniques involving molecular dynamics (MD) simulation and NMR measurement, we uncover a new SOS1’s PR motifs, PKLPPKTYKREH, which shows strong binding to cSH3 but exhibits very weak affinity to nSH3. Unlike the arginine residue in the PXXPXR motif, the lysine residue in the PXXPPKXXKR motif induces weak interaction with cSH3. However, high affinity interaction is mainly derived from the hydrophobic interaction between the PXXP motif and cSH3, indicating the different binding modes of interaction. Our results suggest that Grb2 nSH3/cSH3 bind to SOS1 at distinct locations and provide atomic detailed models of Grb2-SOS1 association. Recent Grb2 targeted therapy reveals that peptide inhibitors, which interrupt Grb2-SOS1 interaction, effectively prevent the migration of breast cancer cell. The mechanism of Grb2-SOS1 interaction may enlighten the promising drug treatment development. Citation Format: Tsung-Jen Liao, Hyunbum Jang, Ruth Nussinov, David Fushman. A new discovering motif on SOS1 PR domain clues Grb2-SOS1 association [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 5145.
AUTHORS' REPLY
Authors: M. Miller, A. Pincock
Journal: Thorax (1989)

7) advocates reporting lung function in standard deviation units.This approach is statistically valid when the subject whose results are under scrutiny is selected at random.Oldham, however, has pointed out that people who become patients often do so because they are at increased risk; in these circumstances there is no compelling logic in the use of standard deviation units.'Their use is implicit in the definition of normal lung function adopted by the European Society for Clinical Respiratory Physiology2 and formerly by the American Thoracic Society (ATS).But the ATS has now reverted to defining a normal result as one which is not more than 20% below the reference value.The use of percentages has the apparent advantage that loss of lung function can be readily classified as mild, moderate, or severe, in the case of FEV, with cut off points at 80%, 60%, and 40% of the reference value.These grades are then equated with loss of exercise capacity.3Unfortunately, extrapolation from lung function to disability is not suppor- ted by evidence,4 and use of SD units does not overcome the difficulty.5That the extrapolation is made at all indicates a need to consider how lung function results should be used and how reference values should be chosen for different applications.Your editorial only starts to address this issue and more needs to be done.
Anti-KIR Antibody Enhancement Of Anti-Lymphoma Activity Of Natural Killer Cells As Monotherapy and In Combination With Anti-CD20 Antibodies
Authors: Holbrook E Kohrt, Ariane Thielens, Aurelien Marabelle, Idit Sagiv Barfi, Caroline Sola, Fabien Chanuc, Nicolas Fuseri, Cécile Bonnafous, Debra K Czerwinski, Amanda Rajapaksa, Erin Waller, Sophie Ugolini, Eric Vivier, Francois Romagne, Ronald Levy, Pascale Andre, Mathieu Blery
Journal: Blood (2013)
Elements de Semeiologie Infantile.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Annals of Internal Medicine, Philadelphia
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Foreign Bodies in the Auditory Canal
Journal: New England Journal of Medicine (1966)

To the Editor:\p=m-\MaryB., aged 5 years, of German parentage, was brought to my office by her father recently.He gave a history that the child had complained for several months of ear trouble, and especially of the left ear, and at times suffered with ear ache.An examination with speculum and reflected artificial light, revealed what was first supposed to be hard- ened cerumen.Copious syringing and douching failed to dis- lodge it and a closer examination and contact of the substance with the ear spoon disclosed a hard, smooth surface, and the
Assessment of adherence to mesalazine maintenance therapy over 1 year using memscaps monitoring system: a substudy of the coda trial comparing once- versus three times daily asacol in ulcerative colitis (UC)
Authors: A. B. Hawthorne, R. Stenson, D. Gillespie, K. Kapur, K. Hood, C. S. Probert
Journal: Gut (2011)

<h3>Introduction</h3> The Colitis Once Daily Asacol (CODA) study assed the efficacy and safety of once daily dosing with Asacol 2.4 g (3 × 800 mg tablets) (OD) versus three times daily. Emerging evidence suggests OD mesalazine is as effective as divided doses. This has been attributed to better adherence, but detailed measures of adherence were lacking in previous studies. The Medication Event Monitoring System (MEMS) based in a bottle cap records the time each time the bottle is opened, giving detailed adherence data. <h3>Methods</h3> 213 UC patients were followed for 1 year or until relapse. A subgroup used the MEMS bottle caps to record treatment adherence. Bottle opening (dosage event) was assumed to equate to tablet consumption. Analysis was performed on the complete case population (CCP). Daily adherence was defined for OD as one dosage event within 24 h, and for three times daily as three dosage events, (separated each by &gt;1 h). Cofactors including treatment group, age, sex, employment status, and relapse/non-relapse were explored. Factors affecting relapse were explored in a multivariable regression model. <h3>Results</h3> 58 entered the substudy, and used the MEMS system (OD 28, three times daily 30). In 49, complete data was collected (1 year or to relapse) and 9 had partial data. For the CCP 3/27 (11.1%) of the OD group relapsed, versus 13/29 (44.8%) of three times daily group (difference in relapse rates −34% (95% CI −55% to −12%). The % days adherent (median (IQR)) was 94.6% (90.8–96.7%) for OD, and 53.2% (32.0–80.8%) for three times daily (p&lt;0.001). % days adherent did not differ between relapsers/non-relapsers. For OD group relapsers were 96.2% (90.8–96.5%) adherent versus non-relapsers 94.6% (90.8–96.8%); for three times daily group relapsers 42.4% (40.0–84.6%) adherent versus non-relapsers 57.1% (32.0–80.5%). In multivariable regression model of relapse, three times daily dosing affected risk of relapse: OR 6.5 (95%CI 1.3 to 3.5), p=0.024, but % adherence did not (OR 1.0 (95% CI 0.79 to 1.27), p=0.99. There was a strong relation between both perceived adherence and ease of taking medication reported by patients, and measured adherence. Age, sex, centre and employment status did not affect adherence significantly. <h3>Conclusion</h3> Adherence is significantly greater in OD versus three times daily dosing. In this small subgroup of the CODA population, the significantly reduced relapse rates in the OD group are not explained entirely by the improved treatment adherence.